Cellectis
Update in progressCLLS (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Cellectis S.A. is a clinical-stage biotechnological company focused on gene-editing with allogeneic CAR T-cell programs for immuno-oncology and other therapies. Its candidates include BALLI-01 (lasme-cel) for relapsed/refractory ALL, NatHaLi-01 (eti-cel) for relapsed/refractory B-NHL, ALPHA3 for LBCL, TRAVERSE for advanced/metastatic clear cell RCC, and a melanoma program. Founded in 1999, it is headquartered in Paris, France.
Company score
- Sentiment
- -0.16
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.15
- Governance
- -0.19
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.12
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationFrance
- CEODr. Andre Choulika Ph.D.
- Founded1999
- Employees224
- Websitewww.cellectis.com
Identifiers
- ISINUS15117K1034
- FIGIBBG0084L1XN2
- LEI5493000KKX5VQ37Q2W83
- CUSIP15117K103
- CIK0001627281